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DownBackground: Lower urinary melatonin levels are associated with a higher risk of breast cancer in postmen-
opausal women. Literature for premenopausal women is scant and inconsistent.
Methods: In a prospective case-control study, we measured the concentration of 6-sulphatoxymelatonin
(aMT6s) in the 12-hour overnight urine of 180 premenopausal women with incident breast cancer and 683
matched controls.
Results: In logistic regression models, the multivariate odds ratio (OR) of invasive breast cancer for women
in the highest quartile of total overnight aMT6s output compared with the lowest was 1.43 [95% confidence
interval (CI), 0.83-2.45; Ptrend = 0.03]. Among current nonsmokers, no association was existent (OR, 1.00; 95%
CI, 0.52-1.94; Ptrend = 0.29). We observed an OR of 0.68 between overnight urinary aMT6s level and breast
cancer risk in women with invasive breast cancer diagnosed >2 years after urine collection and a significant
inverse association in women with a breast cancer diagnosis >8 years after urine collection (OR, 0.17; 95% CI,
0.04-0.71; Ptrend = 0.01). There were no important variations in ORs by tumor stage or hormone receptor status
of breast tumors.
Conclusion: Overall, we observed a positive association between aMT6s and risk of breast cancer. How-
ever, there was some evidence to suggest that this might be driven by the influence of subclinical disease on
melatonin levels, with a possible inverse association among women diagnosed further from recruitment.
Thus, the influence of lag time on the association between melatonin and breast cancer risk needs to be eval-
uated in further studies. Cancer Epidemiol Biomarkers Prev; 19(3); 729–37. ©2010 AACR.Introduction
Secretion of melatonin, an indoleamine hormone that
is produced primarily by the pineal gland, follows a
rhythm of ∼24 hours with most production occurring
during the dark phase of a light-dark cycle (1). Circadian,
that is ∼24-hour, rhythms (2) drive some of the most
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on August 28, 2019cebp.aacrjournals.org loaded from ulated by a circadian pacemaker located in the hypothal-
amus (3), of which melatonin is thought to be a surrogate
marker. The urine concentration of the major metabolite
of melatonin, 6-sulphatoxymelatonin (aMT6s), is highly
correlatedwithmelatonin levels in blood and saliva (4-10).
Results of previous studies (reviewed in ref. 11) sug-
gest that night-shift work, a surrogate for exposure to
light at night, is associated with an increased risk of
breast cancer (12). Following earlier suggestions by
Cohen et al. of a role of melatonin in the induction of
breast tumors (13) and on the basis of results of labora-
tory and animal experiments (14-16), light-induced
suppression of melatonin secretion has been hypothe-
sized as the major cause of this association; however,
although associations among postmenopausal women
consistently suggest a lower risk of breast cancer with
higher melatonin levels (17, 18), the only two prospec-
tive studies conducted to date to study associations be-
tween circulating melatonin and premenopausal breast
cancer risk showed inconsistent results: one study
found no evidence that 24-hour urinary levels of mel-
atonin are strongly associated with the risk of breast
cancer (19), whereas the other study reported their first
morning urinary levels of melatonin to be strongly and
inversely related to risk of breast cancer (20).729
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Published OnlineFirst March 3, 2010; DOI: 10.1158/1055-9965.EPI-09-1229 We used a nested case-control design to conduct a
prospective study of the association between melatonin
levels in 12-hour overnight urine and breast cancer risk
in a large cohort of premenopausal women enrolled in
Hormones and Diet in the Etiology of Breast Cancer Risk
(ORDET). We evaluated associations between total
aMT6s produced between 7:00 p.m. and 7:00 a.m. and
creatinine-adjusted aMT6s measured in overnight urine
and premenopausal breast cancer risk.
Materials and Methods
The ORDET cohort was established in Northern Italy
between June 1987 and June 1992, when 10,786 healthy
women ages 35 to 69 y were enrolled (21, 22). They were
all residents of the Varese province, an area covered by
the Lombardy Cancer Registry (23), who had heard
about the study through the media, at public meetings,
and at breast cancer early detection centers, and who vo-
lunteered to participate. At recruitment, several baseline
characteristics including demographics and dietary in-
takewere queried from each participant through question-
naire; direct measurements of several anthropometric
variables including height and weight were conducted;
and blood and urine specimens were collected. Because
of the focus of the study on endogenous hormones and
their relationship with breast cancer risk, stringent inclu-
sion criteria were established and highly standardized
conditions on collecting biological samples were applied.
Women were excluded if they reported a bilateral ovariec-
tomy, were currently breast feeding or pregnant, used oral
contraceptives or hormone replacement therapy in the last
3 mo, were affected by chronic or acute liver disease, or re-
ported a history of cancer.
Cancer incidence information, available from the local
cancer registry (Varese Cancer Registry) was linked to the
ORDETcohort to identify incident breast cancer cases up to
December 2003. The Varese Cancer Registry is of high qual-
ity: <2% of breast cancer cases are known to the registry by
death certificate only, and the histology and cytology of
96.3% of all cases has been confirmed through pathology
reports (21, 24). TheORDET file was also linked to the Var-
ese residents' file to check the participants' vital status.
After exclusion of women with a history of cancer
(with the exception of nonmelanoma skin cancer) and
women who, immediately after baseline, were lost to fol-
low-up (observed time, 0), 10,633 participants remained
to form the base population of ORDET. For this study, we
further restricted the ORDET cohort to its 6,667 premen-
opausal participants. Women were considered premeno-
pausal when they reported having any menstrual cycle
over the past 12 mo. Participants were censored at the
time of cancer diagnosis, death, or loss to follow-up,
whichever came first (median follow-up time, 15.4 y).
Selection of Case and Control Subjects
Case and control subjects were selected from among all
6,667 eligible premenopausal women. Case subjects wereCancer Epidemiol Biomarkers Prev; 19(3) March 2010
on August 28, 2019cebp.aacrjournals.org Downloaded from women who developed breast cancer after their recruit-
ment into the ORDET cohort but before the end of the
study period (December 31, 2003). We identified a total
of 238 incident breast cancer cases. Of these, 58 women
were eliminated because their follicle-stimulating hor-
mone level was indicative of perimenopausal or post-
menopausal status (that is, follicle-stimulating hormone
of >10 μL/mL). Of the remaining 180 cases, 10 had in situ
breast cancer.
For each case subject with breast cancer, four control
subjects were randomly chosen from appropriate risk
sets consisting of all cohort members who satisfied the
matching criteria (age at recruitment of ±3 y, date of re-
cruitment of 180 d, and laboratory batch) and were alive
and free of cancer (except nonmelanoma skin cancer) at
the time of diagnosis of the index case. Matching charac-
teristics were age (±3 y) at enrollment, date of recruitment
(±180 d), and laboratory batch. A total of 683 controls were
selected. An incidence density sampling protocol for con-
trol selection was used, such that controls could include
subjects who became a case later (13 women), whereas
each control subject could also be sampled more than
once (77 women).
Specimen Collection
Women were instructed to collect their urine over the
previous night. They followed a collection protocol that
called for discarding the last void at 7:00 p.m. and collect-
ing urine during the night up to 7:00 a.m. Urines were
collected during the luteal phase of a woman's menstrual
cycle, between day 20 and 24. Overnight urine was kept
at room temperature during collection. After delivery to
the ORDET recruitment center the day after overnight
collection between 7:30 a.m. and 9:00 a.m., all urine sam-
ples were immediately processed and stored at −80°C un-
til biochemical determinations were done. Urine was
filtered and separated, and 2-mL aliquots were stored.
No preservatives were added either at collection or dur-
ing storage. Similarly, blood samples were collected dur-
ing the luteal phase of a woman's menstrual cycle,
between day 20 and 24, after overnight fasting between
7:30 a.m. and 9:00 a.m. and stored at −80°C. This study
was approved by the Ethical Review Board of the Na-
tional Cancer Institute of Milan (Italy).
Laboratory Methods
Stability and reliability of the ORDET collection meth-
od for aMT6s have been shown (25) to be reasonable, al-
though storage temperature affected specimens such as
that urine stored long term at −30°C had systematically
lower aMT6s levels than urine stored at −80°C.
Urine samples from breast cancer cases and related
controls were handled identically and assayed together
on the same day and in the same run. All samples
were taken out of the freezer simultaneously and sent
to the laboratory in the same parcel on dry ice. They
were stored at −80°C for an average of 17 y. Laboratory
personnel were blinded to case-control status. ControlCancer Epidemiology, Biomarkers & Prevention
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standard samples.
Urinary aMT6s was assayed by the Hormone Research
Laboratory, Fondazione Istituto Di Ricovero e Cura a
Carattere Scientifico Istituto Nazionale Tumori (Milan,
Italy), using the Bühlmann ELISA EK-M6S (Bühlmann
Laboratories AG) with a lower detection limit of 0.8
ng/mL for aMT6s.
Creatinine levels were also measured for each sample
by the Medical Laboratory of the Department of Oncolo-
gy, Fondazione Istituto Di Ricovero e Cura a Carattere
Scientifico Istituto Nazionale Tumori (Milan, Italy), with
a Hitachi Modular Automatic Analyzer and optimized
reagents (F. Hoffmann, La Roche Ltd; ref. 26). The aver-
age between-batch coefficient of variation was 5.3% and
10.3% for urinary aMT6s [high and low standard quality
controls (QCs)], and2.7%and 2.1% for creatinine concentra-
tions of 1.2 and 4.37 mg/dl, respectively. The within-batch
coefficient of variations (CVs) derived from the quality
control urine included in the analytic runs were 1.8%
and 9.8% for aMT6s (high and low standard QCs).
Plasma sex steroid measurements (testosterone, free
testosterone, Sex hormone-binding globulin (SHGB),
and estradiol) were conducted by Centro Medico Diag-
nostico Emilia (Bolgona, Italy). For testosterone and free
testosterone, we used Coat-A-Count procedure, a solid-
phase RIA (Diagnostic Product Corp.); for SHGB, we
used IMMUNOLITE 1000 Analyzer, a solid-phase,
chemiluminescent immunometric assay (Diagnostic
Product Corp.); and for estradiol, we used Orion Diag-
nostica SPECTRIA Estradiol Sensitive RIA test, a coated
tube RIA (Orion Diagnostica Oy). Quality control was
done at three concentrations for sex hormone binding
globulin (SHBG) and total and free testosterone and at
four concentrations for total estradiol. In each batch,
quality control samples were evaluated in quadrupli-
cates.Within-batch quality control coefficients of variation
were 5.9% (high concentration) and 14.0% (low concentra-
tion) for estradiol; 5.8% and 10.6%, respectively, for total
testosterone; 7.0% and 9.6%, respectively, for free testoster-
one; and 3.1% and 3.4%, respectively, for SHBG. Average
between-batch coefficients of variation were 7.4% (high)
and 16.4% for estradiol (low), 8.7% and 18.5% for total tes-
tosterone, 14.9% and 17.2% for free testosterone, and 4.9%
and 4.6% for SHBG.Statistical Analyses
In total, 180 case patients with invasive or in situ breast
cancer and 683 matched control subjects were available
for our analyses. We multiplied aMT6s concentration
(ng/mL) with 12-h urine volume to obtain total aMT6s
produced between 7:00 p.m. and 7:00 a.m. (reported as
microgram per 12 h). In secondary analyses, aMT6s le-
vels were normalized to the creatinine level of the sample
to account for differences arising from variations in urine
concentrations (reported as ng aMT6s per milligram of
creatinine).www.aacrjournals.org
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case and control subjects, we used mixed-effects regres-
sion models for clustered data to adjust for possible con-
founding due to the matching factors and for any
residual correlation between case and control subjects
within the matched set (27). We used conditional regres-
sion models to estimate the relative risks of breast cancer
[reported as odds ratios (OR) with 95% confidence inter-
vals (CI)] by quartiles of urinary aMT6s concentrations,
which were defined on the basis of the values for all
control subjects. Multivariate models were adjusted for
known risk factors for breast cancer [see footnote to Table 3].
In secondary analyses, we also adjusted for the sex ster-
oids that we measured in our data set. We tested for
trends by modeling natural aMT6s concentrations con-
tinuously and calculating the Wald statistic. To evaluate
the presence of an interaction between smoking (binary;
current versus past or never smokers) and aMT6s levels
(continuously), we added an interaction term into our
logistic regression model and used the likelihood ratio
test for interaction to determine significance. We used
the SAS version 9.1.3 for all analyses. All P values
were two sided.
Results
Table 1 shows baseline characteristics of the 180 cases
and 683 controls. The mean time between urine collection
and diagnosis was 7.7 years (89 months; SD, 50.5) with a
range of 1 to 185 months. Study participants were all pre-
menopausal with an age range of 35 to 54 years at urine
collection. Most of the women's baseline characteristics
did not differ by case-control status (Table 1). However,
age-adjusted mean urinary aMT6s concentration of the
breast cancer cases was slightly higher than that of con-
trols [17.4 μg aMT6s versus 15.8 μg aMT6s; 29.3 ng
aMT6s/mg creatinine versus 27.6 ng aMT6s/mg creati-
nine]. Table 2 shows age and age-adjusted baseline char-
acteristics by quartiles of urinary overnight aMT6s
(microgram) among the 683 controls included in this
study. Several of the women's baseline characteristics, in-
cluding age, family history of breast cancer, history of be-
nign breast disease, smoking, and body mass index
(BMI), differed modestly by aMT6s quartile (Table 2).
From among several sex steroids, including circulating
plasma testosterone, free testosterone, SHBG, and estra-
diol, none seemed to vary substantially by aMT6s level.
Overall, we observed a positive association between
urinary aMT6s concentrations and breast cancer risk
(OR for highest versus lowest quartile of urinary aMT6s
concentration, 1.53; 95%CI, 0.91-2.56; Ptrend = 0.01; Table 3),
which was modestly attenuated after additional adjust-
ment for breast cancer risk factors including current smok-
ing status (OR, 1.43; 95% CI 0.83-2.45). Night work and
melatonin have been more strongly related to invasive
than in situ breast cancer risk (20, 28-30), andwe, therefore,
excluded 10 cases who were diagnosed with in situ breast
cancer and their matched controls. Among women withCancer Epidemiol Biomarkers Prev; 19(3) March 2010 731
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Published OnlineFirst March 3, 2010; DOI: 10.1158/1055-9965.EPI-09-1229 invasive breast cancer only, the association was very sim-
ilar (multivariate OR for highest versus lowest quartile of
urinary aMT6s concentration, 1.39; 95% CI, 0.90-2.41;
Ptrend = 0.04) and we therefore kept these 10 cases in all
subsequent analyses.
When we evaluated the influence of sex steroid hor-
mones on these associations, none of the hormones pre-
viously found to predict premenopausal breast cancer
risk was correlated with urinary aMT6s to a meaningful
degree (all Spearman rank correlations ≤0.08: r = −0.08,
P = 0.02 for testosterone; r = 0.02, P = 0.49 for free testos-
terone; r = −0.06, P = 0.11 for estradiol; and r = −0.01, P =
0.85 for SHBG). Further adjustment for testosterone, free
testosterone, estradiol, or SHBG in our multivariate re-
gression models did not alter our estimates substantially
(data not shown).
Based on a previous study suggesting that the noctur-
nal plasma melatonin increase inversely correlates with
tumor estrogen receptor (ER) concentration (31), we con-
ducted analyses stratified on ER status. For 169 of all 180
premenopausal breast cancer cases, hormone receptor
status was available, and for 164 cases, HER2 status
was available. Of these, 66.9% were ER-positive tumorsCancer Epidemiol Biomarkers Prev; 19(3) March 2010
on August 28, 2019cebp.aacrjournals.org Downloaded from (only 56 women had ER-negative breast tumors), and
79.3% were HER2 negative (only 34 women had HER2-
positive breast tumors). When we restricted the analysis
to women with ER-positive breast tumors, the positive
association between aMT6s and breast cancer risk was
virtually the same (multivariate OR for highest versus
lowest quartile of urinary aMT6s, 1.44; 95% CI, 0.67-
3.08) and remained by and large unchanged when we
restricted towomenwithHER2-negative tumors (multivar-
iateOR for highest versus lowest quartile of urinary aMT6s,
1.84; 95% CI, 0.94-3.60). Similarly, although based on only
19 cases in the upper quartile, the risk of ER-negative breast
cancer seemed highest among women in the highest quar-
tile of aMT6s (OR, 2.16; 95% CI, 0.78-6.00).
We found no effect modification by age (stratified
along the median, ages <43 and ≥43 years) or BMI (strat-
ified along the median, 24.4). Because a previous study
suggested that cigarette smoking affects melatonin pro-
duction in premenopausal women (32), we further strati-
fied by smoking status. Among never or past smokers, we
observed no association between urinary melatonin levels
and breast cancer risk (highest versus lowest quartile of
urinary aMT6s concentration, 1.00; 95% CI, 0.52-1.94;Table 1. Baseline characteristics of 180 premenopausal women with invasive (n = 170) or in situ (n = 10)
breast cancer and their 683 matched controlsAll women. ©Cases (n = 180)Cancer Epidemiology, Bioma
 2010 American Association for CaControls (n = 683)Age, y 43.4 (4.3) 43.1 (4.3)
Urinary aMT6s, ng/mL creatinine 29.3 (1.11) 27.6 (0.57)
Urinary aMT6s/12 h, μg 17.4 (0.61) 15.8 (0.31)
Age at menarche, y 12.6 (1.4) 12.6 (1.4)
Parity (among parous women only; %) 1.9 (0.8) 2.0 (0.8)
Age at first birth (among parous women only) 22.8 (9.4) 22.7 (9.0)
Family history of breast cancer (%) 9.4 7.6
OC use (%) 45.3 41.9
BMI, kg/m2 24.3 (4.4) 24.4 (4.0)
Alcohol consumption, g/d 9.4 (13.0) 8.8 (12.8)
History of benign breast disease (%) 31.1 27.2
Education beyond 8 y of elementary school (%) 41.7 31.7
Smoking history
Current smoker (%) 20.0 24.5
Past smoker (%) 20.0 12.5
Never smoker (%) 60.0 63.0
Pack-years among ever smokers 9.6 (9.0) 9.4 (10.1)Sex hormone levels
SHBG (nmol/L) 65.7 (2.1) 67.3 (1.1)
Testosterone (ng/mL) 0.29 (0.01) 0.28 (0.06)
Free testosterone (pg/mL) 0.71 (0.03) 0.69 (0.02)
Estradiol (pg/mL) 90.8 (3.9) 95.3 (2.0)
FSH (μg/mL) 4.1 (0.12) 4.0 (0.06)
LH (μg/mL) 2.5 (0.14) 2.7 (0.07)NOTE: Mean (SD) of Baseline characteristics of 180 premenopausal women was shown and their 683 controls.
Abbreviation: OC, oral contraceptive; FSH, follicle-stimulating hormone; LH, luteinizing hormone.rkers & Prevention
ncer Research. 
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Published OnlineFirst March 3, 2010; DOI: 10.1158/1055-9965.EPI-09-1229 Ptrend = 0.29; Table 3). By contrast, we observed a positive
association among women who reported cigarette smok-
ing at the time of urine collection [highest versus lowest
quartile of urinary aMT6s concentration, age-adjusted
OR, 2.84; 95% CI, 0.43-18.8; Ptrend = 0.14; χ
2 from Log-
likelihood (LLH) ratio test for interaction between smok-
ing and aMT6s, 1.22, P (1 degree of freedom) = 0.27],
although power was limited in these analyses with only
36 breast cancer cases among current smokers.
Next, to rule out the possibility of preclinical tumors
influencing our aMT6s levels, we excluded cases that
were diagnosed shortly after urine collection, using a
stepwise approach (Table 3). In these analyses, the asso-
ciation between urinary aMT6s level and breast cancer
risk became increasingly inverse after excluding case pa-
tients who were diagnosed with invasive breast cancer
within 2 years (OR for highest versus lowest quartile of
urinary aMT6s concentration and risk of breast cancer
developed at least >2 years after urine collection, 0.68;
95% CI, 0.32-1.44; Ptrend = 0.63), 4 years (OR for highest
versus lowest quartile of urinary aMT6s concentration,
0.61; 95% CI, 0.26-1.39; Ptrend = 0.80), or 8 years after
urine collection (OR for highest versus lowest quartile
of urinary aMT6s concentration, 0.17; 95% CI, 0.04-0.71;www.aacrjournals.org
on August 28, 2019cebp.aacrjournals.org Downloaded from Ptrend = 0.01), although the latter analysis was based on
12 cases only in the upper quartile. By contrast, when re-
stricting to women who developed breast cancer within
3 years after urine collection (28 cases; there were only 14
and 24 cases diagnosed within 1 and 2 years after urine
collection, respectively, limiting our power to explore
these associations), the association with breast cancer risk
was strongly positive among those with the highest mel-
atonin levels (OR for highest versus lowest quartile of
urinary aMT6s concentration, 14.8; 95% CI, 1.39-157;
Ptrend = 0.03). The lack of an association between melato-
nin and breast cancer risk that we observed in the overall
data set (that is, including past and current smokers) re-
mained unchanged throughout these secondary analyses
when smokers were included (data not shown). Of all tu-
mors, 92 were histopathologically classified as localized
and 51 as metastatic—the remaining 27 were of unknown
tumor stage. Further analyses stratifying by localized
versus metastasized breast tumors did not reveal any ef-
fect modification by tumor stage (data not shown).
In secondary analyses, we also evaluated associations
between creatinine-adjusted aMT6s and breast cancer
risk. Creatinine-adjusted and total aMT6s were highly
correlated (Spearman r = 0.75,P< 0.001) and bothmeasuresTable 2. Age and age-adjusted baseline characteristics of 683 controls by quartiles of urinary aMT6s levelAll control women Quartiles of 12-h overnight urinary aMT6s output (μg)Q1 (n = 170). © 201Q2 (n = 171)Cancer Epidemiol
0 American AssocQ3 (n = 172)Biomarkers Prev; 19
iation for Cancer Q4 (n = 170)Range of urinary aMT6s output/12 h (μg) <10.1 10.1-14.6 14.7-20.5 ≥20.6
Age, y 43.8 43.0 42.4 43.3
Age at menarche, y 12.8 12.6 12.6 12.5
Parity (no. of children, among parous women only) 2.1 2.0 1.9 1.9
Age at first birth (among parous women only) 25.4 24.9 26.1 26.1
Family history of breast cancer (%) 8.8 7.0 5.8 8.8
OC use (%) 38.9 45.9 37.7 47.7
BMI, kg/m2 24.6 24.4 24.5 24.2
Alcohol consumption, g/d 8.0 7.8 11.7 7.7
History of benign breast disease (%) 29.4 29.8 25.6 24.1
Education beyond 8 y of elementary school (%) 31.9 28.6 30.2 35.9
Smoking history
Current smoker (%) 27.1 24.0 24.4 22.4
Past smoker (%) 6.5 14.0 14.0 15.3
Never smoker (%) 66.5 62.0 61.6 62.4
Pack-years among ever smokers 12.9 9.8 7.5 7.9Sex hormone levels
SHBG (nmol/L) 64.7 68.6 68.2 67.8
Testosterone (ng/mL) 0.30 0.29 0.29 0.25
Free testosterone (pg/mL) 0.72 0.68 0.70 0.65
Estradiol (pg/mL) 98.1 97.7 95.4 90.1
FSH (μg/mL) 4.1 4.1 4.0 3.7
LH (μg/mL) 2.8 3.0 2.8 2.3NOTE: Mean of age and other baseline characteristics are shown.(3) March 2010 733
Research. 
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Published OnlineFirst March 3, 2010; DOI: 10.1158/1055-9965.EPI-09-1229 also correlatedwellwith crude aMT6s concentration (r=0.61
and 0.73, respectively, both P < 0.001). In multivariate anal-
yses, we observed a positive association between creatinine-
adjusted urinary aMT6s and invasive breast cancer risk
(OR for highest versus lowest quartile of total urinary
aMT6s, 1.67; 95% CI, 0.99-2.82; Ptrend = 0.27), a risk which
was alsomarkedly attenuated among never and past smo-
kers (highest versus lowest quartile of creatinine-adjusted
urinary aMT6s, 1.21; 95% CI, 0.65-1.25; Ptrend = 0.98).Cancer Epidemiol Biomarkers Prev; 19(3) March 2010
on August 28, 2019cebp.aacrjournals.org Downloaded from Urinary creatinine concentration is influenced by sev-
eral factors including gender, ethnicity, age and BMI (33).
Although our study was exclusively composed of Cauca-
sian women, differences in age and BMI may have biased
our creatinine-adjusted aMT6s measure. There was only
a modest correlation between creatinine-adjusted aMT6s
and creatinine (Spearman r = −0.15, P < 0.001), suggest-
ing the potential for bias introduced by adjusting for cre-
atinine to be small.Table 3. ORs and 95% CIs of breast cancer by quartile of total 12-h overnight aMT6s output [aMT6s
concentration (ng/mL) multiplied with 12-h volume in mL]Group and parameter Quartile1 2Cancer
. © 2010 Ameri3Epidemiology, B
can Association 4iomarkers & Pr
for Cancer ResePtrend*Urinary aMT6s output/12 h (μg) <10.1 10.1-14.6 14.7-20.5 ≥20.6
No. of case patients/no. of control subjects 39/170 34/171 55/172 52/170
Invasive and in situ breast cancer cases
Simple OR* 1.00 (Reference) 0.91 (0.54-1.53) 1.50 (0.92-2.45) 1.53 (0.91-2.56) 0.01
Multivariate OR† 1.00 (Reference) 0.88 (0.51-1.50) 1.43 (0.85-2.42) 1.43 (0.83-2.45) 0.03Excluding current smokers
No. of case patients/no. of control subjects 32/96 27/107 44/106 41/114
Simple OR† 1.00 (Reference) 0.75 (0.41-1.36) 1.24 (0.70-2.20) 1.16 (0.63-2.15) 0.19
Multivariate OR‡ 1.00 (Reference) 0.72 (0.38-1.38) 1.11 (0.59-2.08) 1.00 (0.52-1.94) 0.29Multivariate lagtime analyses among nonsmokers
No. of case patients/no. of control subjects 5/35 4/29 8/33 11/35
Multivariate OR‡ among women diagnosed
within 3 y from urine collection1.00 (Reference) 0.90 (0.09-8.75) 1.88 (0.23-15.3) 14.8 (1.39-157) 0.03No. of case patients/no. of control subjects 30/73 24/82 41/81 35/89
Multivariate OR‡ 1 y lag time 1.00 (Reference) 0.61 (0.30-1.23) 1.07 (0.54-2.12) 0.90 (0.45-1.82) 0.40No. of case patients/no. of control subjects 28/65 24/79 38/75 30/83
Multivariate OR‡ 2 y lagtime 1.00 (Reference) 0.58 (0.28-1.19) 0.95 (0.47-1.94) 0.68 (0.32-1.44) 0.63No. of case patients/no. of control subjects 27/61 23/78 36/73 30/79
Multivariate OR‡ 3 y lagtime 1.00 (Reference) 0.51 (0.24-1.08) 0.87 (0.42-1.82) 0.69 (0.32-1.48) 0.52No. of case patients/no. of control subjects 24/53 19/73 33/67 28/68
Multivariate OR‡ 4 y lag time 1.00 (Reference) 0.41 (0.18-0.92) 0.76 (0.34-1.66) 0.61 (0.26-1.39) 0.80No. of case patients/no. of control subjects 23/52 19/64 28/65 27/62
Multivariate OR‡ 5 y lag time 1.00 (Reference) 0.47 (0.20-1.09) 0.66 (0.29-1.48) 0.66 (0.28-1.54) 0.93No. of case patients/no. of control subjects 20/44 17/57 25/57 23/51
Multivariate OR‡ 6 y lag time 1.00 (Reference) 0.46 (0.18-1.14) 0.68 (0.28-1.64) 0.75 (0.29-1.92) 0.79No. of case patients/no. of control subjects 19/40 16/51 22/47 16/46
Multivariate OR‡ 7 y lag time 1.00 (Reference) 0.43 (0.16-1.17) 0.53 (0.19-1.47) 0.38 (0.13-1.11) 0.13No. of case patients/no. of control subjects 18/31 15/46 18/39 12/36
Multivariate OR‡ 8 y lag time 1.00 (Reference) 0.25 (0.07-0.90) 0.29 (0.07-1.10) 0.17 (0.04-0.71) 0.01*We tested for trends by modeling aMT6s concentrations continuously and calculating the Wald statistic.
†Simple conditional logistic regression model adjusting for the matching variables [year of birth, month and year of urine collection,
and laboratory batch].
‡Multivariate conditional logistic regression models; relative risks were adjusted for the following breast cancer risk factors: BMI in
six categories (≤21, 21.1-23, 23.1-25, 25.1-27, 27.1-30, >30), history of benign breast disease (yes/no), family history (mother or
sister) of breast cancer (yes/no), smoking history (never, past, current), age at menarche in four categories (≤12, 13, 14, 15+),
alcohol consumption per day in grams, three categories (none, ≤12, >12), years of oral contraceptive use (never, ≤1 y, >1 y), parity
in three categories (nulliparous, 1-2, 3+ children), age at first birth in three categories (<20, 20-24, ≥25), and participant's educa-
tional status in years of schooling, three categories [≤5 y (elementary school), 8 y (superior education), >8 y].evention
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Overall, we found a positive association between over-
night urinary aMT6s and breast cancer risk. However,
we found a significant inverse association between over-
night urinary aMT6s and breast cancer risk in premeno-
pausal women, but only in nonsmokers and after
allowing for sufficient (8 year) lag time between urine
collection and the diagnosis of breast cancer. These find-
ings suggest that there might be an influence of subclin-
ical disease on melatonin levels with a possible inverse
association being seen among women diagnoses further
from recruitment.
Few prior studies have evaluated the association be-
tween circulating melatonin levels and breast cancer risk
in humans and most are limited by the fact that melato-
nin levels were measured after the subjects were diag-
nosed with breast cancer (6, 31, 34-43). The first report
to evaluate an association between circulating melatonin
levels and breast cancer risk in 10 women was conducted
by Bartsch et al. in 1981 (36). It found in a small sample of
women with advanced breast cancer, when compared
with healthy controls, that they had lower levels of uri-
nary melatonin (36). Subsequently, Tamarkin et al. (31)
found that women with ER-positive breast cancer had a
reduced nocturnal increase in melatonin, and observed
an inverse correlation between ER levels and peak mela-
tonin values. Several subsequent studies examined mela-
tonin levels in cancer patients (6, 31, 34-43). Because
blood samples for melatonin were typically collected af-
ter a diagnosis of cancer in these retrospective studies,
they are limited in their ability to assess the predictive
value of the hormone for breast cancer risk. However, da-
ta from nontreated patients with localized breast cancer
provide evidence for a depression of the nocturnal surge
of melatonin that parallels an increase in tumor size and
the development of distant metastases (34, 35, 37). To-
gether with evidence from nontreated primary prostate
cancer patients, in which melatonin levels were particu-
larly high if well-differentiated G1 (incidental) carcino-
mas were present (44), these observations suggest
complex interactions between the pineal gland and tu-
mor growth. Melatonin has a potential role in different
phases of carcinogenesis such as initial activation, inhibi-
tion of tumor growth, and restimulation as cancer cells
disseminate; this complexity may account for apparent
inconsistencies found in prospective studies.
More recently, evidence from prospective case-control
studies nested in larger cohorts has been published. An
Italian case-control study nested within the ORDET co-
hort assessed the concentration of the major metabolite
of melatonin, aMT6s, in 178 postmenopausal women
with incident invasive breast cancer and 710 matched
controls. The multivariate relative risk for women in
the highest quartile of total overnight aMT6s output com-
pared with the lowest was 0.56 (95% CI, 0.33-0.97). In this
report, overnight urinary aMT6s level andbreast cancer risk
were more strongly associated in women who were diag-www.aacrjournals.org
on August 28, 2019cebp.aacrjournals.org Downloaded from nosed with invasive breast cancer >4 years after urine col-
lection (OR, 0.34 highest versus lowest quartile; 95% CI,
0.15-0.75; ref. 45). A second case-control study in postmen-
opausal women was conducted nested within the NHS co-
hort (17). In that study, aMT6s levels were available for 357
postmenopausal women who developed incident breast
cancer along with 533 matched control subjects. An in-
creased concentration of urinary aMT6s was statistically
significantly associated with a lower risk of breast cancer
with an OR for the highest versus lowest quartile of morn-
ing urinary aMT6s of 0.62 (95%CI, 0.41-0.95; Ptrend = 0.004).
Evidence for an association between urinary melatonin
and breast cancer risk among premenopausal women is
also sparse and has been less consistent, perhaps in part
due to varying urine sampling methods used in these
studies. Only two prospective studies have evaluated
the associations, one of which did not find an increased
risk (19), whereas the other one described a significantly
reduced risk of breast cancer risk in women with the
highest melatonin levels. In the first study, a prospective
study of urinary 6MTs in 77 cases and 214 premeno-
pausal controls matched for age, recruitment date, day
of menstrual cycle, the OR for breast cancer was 0.99
(95% CI, 0.45-2.17), comparing the highest to the lowest
category (19). This study used 24-hour urine collection, in
contrast to the NHS II, which used first-morning urine
samples (20). The use of 24-hour urine may decrease
the power to detect potential differences by case-control
status, but the confidence limits of this study do not pre-
clude an effect of melatonin on breast cancer risk. More-
over, no lag time analyses were conducted in this study.
In the NHS II cohort, finally, aMT6s levels were mea-
sured in the first-morning urine of 147 women with inva-
sive breast cancer and 291 matched control subjects. The
OR for women in the highest quartile of urinary aMT6s
was 0.59 compared with those in the lowest quartile, and
remained unchanged after adjusting for several important
confounding factors (46). Ameta-analysis of all five (includ-
ingours, excludingcases thatwerediagnosedwithin2years
after urine collection) prospective studies published, to
date, suggests a 34% significant risk reduction of breast
cancer with the highest category of aMT6s (Fig. 1).
We were able to consider most important breast cancer
risk factors in our analyses. Excluding cases diagnosed
with increasing years after urine collection altered our
findings; we observed increasingly stronger risk reduc-
tions with longer time between urine collection and
breast cancer diagnosis, suggesting that perhaps particu-
larly in premenopausal women, their typically more rapid
and aggressive tumor growth that is in part attributable to
differences in the prevalence of molecular breast cancer
subtypes (47) may mask the predictive power of aMT6s
for breast cancer risk breast cancer risk as it also seems
to constitute amarker for tumor growth. Alternatively, be-
cause those women in whom we observed the strongest
associationswere in large part postmenopausal at the time
of diagnosis, this could either argue for a stronger effect of
melatonin on breast tumors with featuresmore commonlyCancer Epidemiol Biomarkers Prev; 19(3) March 2010 735
. © 2010 American Association for Cancer Research. 
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histology) or for a role of change in menopausal status.
The apparent need to lag time between specimen collec-
tion and breast cancer diagnosis may, in addition to vary-
ing urine sampling methods (that is, 24-hour versus
overnight urine), explain the null finding in one (19) of
the other two studies describing the association between
melatonin andbreast cancer risk inpremenopausalwomen.
Although we did not observe a significant interaction
between smoking and aMT6s levels in this data set, it is
similar in magnitude and direction as in a previous anal-
ysis (48) and further underlines the necessity to consider
that various external influences including metabolization
rate, possibly altered by smoking (49, 50), can influence a
urinary marker such as aMT6s.
Our study is limited by the absence of information on
light exposure at night including night work status; thus,
we cannot adjust for this factor. Another potential limita-
tion of our study is that we did not have information on
vitamin D status in our study subjects, another possibleCancer Epidemiol Biomarkers Prev; 19(3) March 2010
on August 28, 2019cebp.aacrjournals.org Downloaded from breast cancer risk factor (51, 52). The relationship be-
tween melatonin levels and vitamin D is unclear, but if
one exists, it could have influenced our results. For exam-
ple, it is conceivable that women with low morning mel-
atonin levels (if due to an altered sleep-wake cycle) also
have particularly low levels of vitamin D mediated by
low sun exposure or differences in dietary habits.
Our findings show that melatonin secretion, as assessed
by aMT6s levels in 12- hour overnight urine, is associated
with a reduced risk of developing premenopausal breast
cancer but only if long enough lag times are applied. Thus,
although evidence for an association between melatonin
and breast cancer risk continues to accumulate, further
studies are needed to evaluate the influence of lag time
on the association between melatonin and breast cancer
risk. These studies should have long enough follow-up
to address the time between urine collection (as an appar-
ently healthy person) and cancer diagnosis, as it is conceiv-
able that melatonin secretion is stimulated during early
subclinical stages of tumor development.Disclosure of Potential Conflicts of Interest
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